Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer

Breast Cancer

Volumn 24, Issue 5, 2017, Pages 667-672

  Inoue, Masayuki ^a   Nakagomi, Hiroshi ^a   Nakada, Haruka ^a   Furuya, Kazushige ^a   Ikegame, Kou ^a   Watanabe, Hideki ^a   Omata, Masao ^a,b   Oyama, Toshio ^a  

^a Yamanashi Prefectural Central Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Invasive lobular carcinoma (ILC); Metastatic breast cancer; Peritoneal metastases

Indexed keywords

BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HORMONE RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PROGESTERONE RECEPTOR; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ERBB2 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; LOBULAR CARCINOMA; LONGITUDINAL STUDY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEDIAN SURVIVAL TIME; METASTATIC BREAST CANCER; PATIENT SELECTION; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL RATE; AGED; BREAST TUMOR; COMPARATIVE STUDY; FEMALE; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PERITONEUM TUMOR; PROGNOSIS; SECONDARY; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85009876968     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-017-0753-4     Document Type: Article

References (27)

1. Ashikari R, Huvos AG, Urban JA, Robbins GF. Infiltrating lobular carcinoma of the breast. Cancer. 1973;31:110–6.
2. Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T, et al. Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996;77:113–20.
3. Martinez V, Azzopardi JG. Invasive lobular carcinoma of the breast: incidence and variants. Histopathology. 1979;3:467–88.
4. Fu L, Tsuchiya S, Matsuyama I, Ishii K. Clinicopathologic features and incidence of invasive lobular carcinoma in Japanese women. Pathol Int. 1998;48:348–54.
5. Jung SY, Jeong J, Shin SH, Kwon Y, Kim EA, Ko KL, et al. The invasive lobular carcinoma as a prototype luminal A breast cancer: a retrospective cohort study. BMC Cancer. 2010;10:664.
6. Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE. Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000;88:2561–9.
7. Chen CL, Weiss NS, Newcomb P, Barlow W, White E. Hormone replacement therapy in relation to breast cancer. JAMA. 2002;287:734–41.
8. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149–56.
9. Horsfall DJ, Tilley WD, Orell SR, Marshall VR, Cant EL. Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. Br J Cancer. 1986;53:23–8.
10. Garcia-Fernandez A, Lain JM, Chabrera C, Garcia Font M, Fraile M, Barco I, et al. Comparative long-term study of a large series of patients with invasive ductal carcinoma and invasive lobular carcinoma. Loco-regional recurrence, metastasis, and survival. Breast J. 2015;21:533–7.
11. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008;26:3006–14.
12. Mersin H, Yildirim E, Gulben K, Berberoglu U. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol. 2003;29:390–5.
13. Yagi Y, Sasaki S, Yoshikawa A, Tsukioka Y, Fukushima W, Fujimura T, et al. Metastatic gastric carcinoma from breast cancer mimicking primary linitis plastica: a case report. Oncol Lett. 2015;10:3483–7.
14. Jones GE, Strauss DC, Forshaw MJ, Deere H, Mahedeva U, Mason RC. Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature. World J Surg Oncol. 2007;5:75.
15. Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50:23–30.
16. Lamovec J, Bracko M. Metastatic pattern of infiltrating lobular carcinoma of the breast: an autopsy study. J Surg Oncol. 1991;48:28–33.
17. Veronesi U, Viale G, Rotmensz N, Goldhirsch A. Rethinking TNM: breast cancer TNM classification for treatment decision-making and research. Breast. 2006;15:3–8.
18. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474–81.
19. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.
20. Fisher ER, Gregorio RM, Fisher B, Redmond C, Vellios F, Sommers SC. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975;36:1–85.
21. Krecke KN, Gisvold JJ. Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol. 1993;161:957–60.
22. Molland JG, Donnellan M, Janu NC, Carmalt HL, Kennedy CW, Gillett DJ. Infiltrating lobular carcinoma—a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast. 2004;13:389–96.
23. Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996;13:1919–25.
24. De Leeuw WJ, Berx G, Vos CB, Peterse JL, Van de Vijver MJ, Litvinov S, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol. 1997;183:404–11.
25. Gruel N, Lucchesi C, Raynal V, Rodrigues MJ, Pierron G, Goudefroye R, et al. Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer. 2010;46:2399–407.
26. Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, et al. Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol. 1999;155:337–42.
27. Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121:1348–53.